Dr. Marie Bleakley
Claim this profileFred Hutch/University of Washington Cancer Consortium
Studies Acute Lymphoblastic Leukemia
Studies Acute Leukemia
3 reported clinical trials
14 drugs studied
Area of expertise
1Acute Lymphoblastic Leukemia
HLA-A positive
HLA-A negative
HLA positive
2Acute Leukemia
HLA-A positive
HLA-A negative
HLA positive
Affiliated Hospitals
Clinical Trials Marie Bleakley is currently running
T Cell-Depleted Stem Cell Transplant
for Leukemia
This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.
Recruiting1 award Phase 222 criteria
GVHD-Reduction Strategies
for Blood Cancers
This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.
Recruiting1 award Phase 220 criteria
More about Marie Bleakley
Clinical Trial Related6 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Marie Bleakley has experience with
- Busulfan
- Cyclophosphamide
- Fludarabine
- Methotrexate
- Tacrolimus
- Thiotepa
Breakdown of trials Marie Bleakley has run
Acute Lymphoblastic Leukemia
Acute Leukemia
Biphenotypic Leukemia
Myeloproliferative Disorder
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marie Bleakley specialize in?
Marie Bleakley focuses on Acute Lymphoblastic Leukemia and Acute Leukemia. In particular, much of their work with Acute Lymphoblastic Leukemia has involved HLA-A positive patients, or patients who are HLA-A negative.
Is Marie Bleakley currently recruiting for clinical trials?
Yes, Marie Bleakley is currently recruiting for 2 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Marie Bleakley has studied deeply?
Yes, Marie Bleakley has studied treatments such as Busulfan, Cyclophosphamide, Fludarabine.
What is the best way to schedule an appointment with Marie Bleakley?
Apply for one of the trials that Marie Bleakley is conducting.
What is the office address of Marie Bleakley?
The office of Marie Bleakley is located at: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutch/University of Washington Cancer Consortium.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.